Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Hoffmann-La Roche
Assistance Publique - Hôpitaux de Paris
AbbVie
Diakonhjemmet Hospital
Virtual Tribunal Monastery
University of Aarhus
University of Pittsburgh
Zimmer Biomet
Bristol-Myers Squibb
Bristol-Myers Squibb
Brigham and Women's Hospital
Assistance Publique - Hôpitaux de Paris
M.D. Anderson Cancer Center
Emory University
ProgenaBiome
Universitätsklinikum Hamburg-Eppendorf
Universitaire Ziekenhuizen KU Leuven
Pfizer
Instituto Mexicano del Seguro Social
Future Genetics Limited
University of California, San Diego
University of California, San Diego
Exactech
NHS Greater Glasgow and Clyde
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
VitaMed Research LLC
RemeGen Co., Ltd.
Mabscale, LLC
UCB Pharma
Aalborg University Hospital
Pfizer
Georgetown University
Brigham and Women's Hospital
Rigshospitalet, Denmark
Global Healthy Living Foundation
R-Pharm
King's College London
R-Pharm
Atara Biotherapeutics
St George's, University of London
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Alliance Foundation Trials, LLC.
Ionis Pharmaceuticals, Inc.
Université de Sherbrooke
Peking University Third Hospital
Peking Union Medical College Hospital
Sohag University
Brigham and Women's Hospital
Bristol-Myers Squibb